pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
552
stories
19d
Electra amasses $350M in biotech’s latest big IPO
biopharma dive
19d
Lisata deal propels Marea’s drug pipeline to Wall Street
biopharma dive
19d
Bristol Myers scraps $100M Orum-partnered cancer drug
endpoints
19d
Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
fiercebiotech
19d
North Immunology joins biotech reverse merger boom with Aethlon deal
biopharma dive
19d
Roche eyes label expansion for Lunsumio after confirmatory lymphoma trial win
endpoints
19d
Webinar: Manufacturing in Turbulent Times
biospace
19d
After Novartis’ devastating M&A losses, long live the executive willing to try
biospace
19d
Novartis drops $125M for Sironax’s tech to cross blood-brain barrier
biospace
19d
Roche bets up to $1B to advance next-gen bispecifics with Dualitas
biospace
19d
STAT+: A biotech hedge fund births a new immunology company
stat
19d
Roche, Dualitas team up to find bispecific drugs for immune diseases
biopharma dive
19d
Roche signs $1B deal with Dualitas to pair up on big bispecific screening drive
fiercebiotech
19d
North Immunology goes public via reverse merger as eczema drug heads toward clinic
fiercebiotech
19d
STAT+: England to cover AstraZeneca breast cancer drug, a result of U.K.-U.S. drug pricing deal
stat
20d
Sling banks $123M for an experimental thyroid eye disease pill
biopharma dive
20d
Novartis halts TREM2 targeting ALS program in 4th trial stumble in a month
biospace
20d
Novartis ends ALS program after phase 2 flop, adding to R&D woes
fiercebiotech
21d
Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trial
fiercebiotech
21d
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
biopharma dive
21d
GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M
biospace
21d
GSK lays off 650 staffers amid closure of German vaccine manufacturing site
biospace
21d
Connect's Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope
fiercebiotech
21d
GSK doubles down on Chimagen with $750M multiple myeloma wager
fiercebiotech
22d
Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results
biopharma dive
22d
BioNTech says CTLA-4 drug nearly doubled survival times for lung cancer
endpoints
22d
Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
biospace
22d
Scholar Rock secures first FDA approval for muscle-targeting rare disease drug
biospace
22d
Electra aims for $342M IPO to power inflammatory drug’s push through phase 3
fiercebiotech
22d
Cyclic peptides open new drug frontiers, if manufacturing can keep up
biospace
← prev
page 4 of 19
next →
